Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of Ralliant Corporation regarding potential securities fraud or unlawful business practices following a significant financial impairment announcement [1] Financial Results - On February 4, 2026, Ralliant reported a $1.4 billion non-cash goodwill impairment in its Test & Measurement segment, linked to its acquisition of EA Elektro-Automatik [1] - The impairment was attributed to revised long-term expectations for the EA business and a reduction in industry forecasts for future electric vehicle (EV) adoption [1] Stock Market Reaction - Following the announcement of the impairment, Ralliant's stock price dropped by $17.89 per share, representing a decline of 31.79%, closing at $38.39 per share on February 5, 2026 [1]

We recently published 10 Market Winners With Stunning Gains. Immunitybio Inc. (NASDAQ:IBRX) was one of the best performers on Wednesday. ImmunityBio soared to a new 52-week high on Wednesday, as investors gobbled up shares over an aggressive international expansion for its therapy, Anktiva. At intra-day trading, the stock climbed to its highest price of $8.68 before trimming gains to end the day just up by 41.86 percent at $8.54 apiece. In a statement, Immunitybio Inc. (NASDAQ:IBRX) said that the Europ ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical trial evaluating a novel combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). Meanwhile, on January 26, ImmunityBio Inc. (NASDAQ:IBRX) amended a $505 million convertible promissory note with Nant Capital LLC, allowing the noteholder to convert any portion of the outstanding p ...

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer. Trading volume reached 78.5 million shares, about 178% above its three-month average of 28.2 million shares. ImmunityBio IPO'd in 2015 and has fallen 75% since going public. How the markets moved today The S&P 500 rose 0.53% to finish ...

Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market. Approved... again ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, for the record, when the United States' FDA gave the immunotherapy the green light. The Unite ...

Market Overview - US equity futures resumed their selloff after a brief bounce, with S&P 500 futures down 0.5% and Nasdaq 100 contracts falling 1.0%, driven by concerns over AI disruption [1] - All major tech stocks in the "Magnificent 7" are lower, with notable declines in Nvidia (-0.9%) and Alphabet (-1.5%) [3] - Energy, financials, industrials, and defensive sectors showed pockets of outperformance amid the broader market decline [1] Corporate News - Activist investor Elliott has built a significant stake in Norwegian Cruise Line, leading to a rise of over 7% in its shares [4] - Apple is set to hold a product launch on March 4, which may impact its stock performance [3] - ImmunityBio shares rose 6% after receiving encouragement from the Saudi Food and Drug Authority to submit a regulatory package for its bladder cancer therapy [4] - Masimo shares surged 34% following reports of a nearly $10 billion acquisition deal by Danaher [4] AI and Technology Sector - Investors are cautious about the profitability of AI spending, with concerns about competition and potential disruptions to various industries [6][7] - A record number of investors believe companies are overspending on AI, with 25% citing an "AI bubble" as a top market risk [10] - Despite selloff concerns, two-year forward earnings estimates for software stocks have risen, indicating resilience in the sector [11] Economic Indicators - Upcoming economic data includes the ADP employment change, Empire State manufacturing survey, and NAHB housing market index for February, which could influence market sentiment [1][22] - The UK unemployment rate rose to 5.2%, leading to increased expectations for a Bank of England rate cut [16] Commodities and Geopolitical Factors - Oil prices rose due to geopolitical tensions, particularly military drills by Iran in the Strait of Hormuz, impacting Brent crude prices [13][48] - Gold prices have declined, with spot gold dropping toward $4,900 an ounce amid a risk-off sentiment [1][48]

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) experienced a significant share price increase of 14.55%, closing at $6.93, as investors prepared for its upcoming participation in the American Society of Clinical Oncology (ASCO) event [1][6]. Company Developments - ImmunityBio is set to participate in the 2026 ASCO Genitourinary Cancers Symposium from February 26 to 28 in San Francisco, focusing on research and treatments for genitourinary cancers [2]. - Earlier this year, ImmunityBio reported a remarkable 700% increase in sales from its cancer therapy Anktiva and announced plans to expand operations into Saudi Arabia, where it will sell Anktiva for lung cancer patients following FDA approval [3]. Market Context - Lung cancer is a prevalent cancer type in Saudi Arabia, indicating a significant market opportunity for ImmunityBio's products [3].

Industry Overview - The global oncology market is undergoing rapid transformation due to increasing cancer incidence, demographic changes, and scientific advancements, with an estimated 2.1 million new cancer diagnoses and over 626,000 cancer-related deaths expected in the U.S. in 2026 [2] - Lifestyle-related risk factors and demographic shifts are contributing to a rise in cancer prevalence, leading to sustained growth in oncology healthcare spending [2] Innovation in Cancer Treatment - Advances in immunotherapies, targeted medicines, and personalized vaccines are reshaping cancer treatment, moving beyond traditional chemotherapy and radiation [3] - Immune-based approaches, such as checkpoint inhibitors and CAR-T therapies, utilize the immune system to target tumors, while targeted therapies focus on specific molecular and genetic disease drivers [3] - Technologies like genomic sequencing and AI are enhancing biomarker discovery and patient stratification, leading to earlier diagnoses and improved survival rates across various cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, and Pfizer, are investing heavily in oncology pipelines, developing new therapies such as antibody-drug conjugates and next-generation immuno-oncology treatments [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing deals, and acquisitions [5] Market Resilience - The oncology sector is viewed as one of the most resilient and attractive segments of the global healthcare market for long-term investors, supported by ongoing innovation and favorable reimbursement trends [6] Company Highlights - **ImmunityBio**: Its lead drug, Anktiva, approved in April 2024, generated $113 million in preliminary sales in 2025, with a 750% increase in volumes. The drug is under review in the EU and is being evaluated for expanded use in various cancers [8][9] - **Arcus Biosciences**: Developing casdatifan, a potential best-in-class HIF-2a inhibitor for treating clear cell renal cell carcinoma, with a market opportunity of over $5 billion. Multiple data readouts are expected in 2026 [10] - **Allogene Therapeutics**: Focused on genetically engineered T-cell therapies, with lead candidate cema-cel in a pivotal phase II study for large B-cell lymphoma. Another candidate, ALLO-316, shows early anti-tumor activity in advanced renal cell carcinoma [12][13]

Company Overview - ImmunityBio, Inc. is a U.S. biotechnology company focused on developing next-generation immunotherapies and vaccines aimed at enhancing the natural immune system to combat cancers and infectious diseases [4] Financial Performance - Piper Sandler raised its price target on ImmunityBio, Inc. (IBRX) to $7 from $5, maintaining an Overweight rating [2] - U.S. ANKTIVA net sales surged by nearly 700% year over year, reaching $113 million in 2025, with projected revenue of $180 million in 2026 [2] Clinical Developments - ImmunityBio reported Phase 2 QUILT-3.078 results for recurrent GBM, showing that the longest survival was 12 months, with 19 out of 23 patients still alive [3] - The regimen demonstrated a reasonable safety profile, with preserved immunological competence and improved severe lymphopenia (ALC ≥1.4 ×10³/µL) [3] Future Prospects - There is potential for label expansion for ANKTIVA in 2027, contingent on positive data from the upcoming QUILT-2.005 study expected in Q4 2026 [2][3]

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) has experienced a significant decline of 4.19% on Tuesday, marking the third consecutive day of losses as investors take profits after a 14-day rally [1] - The stock surged by 271% in January due to positive developments, including strong clinical trial results and a 700% increase in sales from its therapy Anktiva [2] - The company is preparing to announce detailed results from its QUILT-3.078 Phase 2 study, which evaluates a chemotherapy-free immunotherapy regimen for patients with recurrent or progressive glioblastoma [3][4] Financial Performance - The recent decline follows a substantial increase in stock value, with a notable 14-day gain prior to the downturn [1] - The treatment under study has shown a manageable safety profile, with 19 out of 23 enrolled patients remaining alive, and four deaths reported [5] Market Position - ImmunityBio's expansion into international markets and the strong performance of its therapy Anktiva have contributed to its recent stock price surge [2] - The company is positioned in a competitive landscape, with some analysts suggesting that other AI stocks may offer better investment opportunities [6]